Trou­bled aTyr ax­es 30% of its staff as it wipes a pre­clin­i­cal slate clean

Faced with dis­ap­point­ing re­sults from its lat­est pre­clin­i­cal pro­gram, aTyr Phar­ma is cut­ting the de­vel­op­ment short and let­ting go around 30% of its staff.

The San Diego-based biotech $LIFE has dis­card­ed IND plans for what would have been its third clin­i­cal pro­gram, dubbed Project OR­CA. In a state­ment, it said the re­struc­tur­ing and oth­er cost-sav­ing mea­sures are aimed at get­ting its sec­ond as­set, ATYR1923, on track for PhII de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER